Balaii Hedieh, Olfatifar Meysam, Olianasab Narab Sepideh, Arab Hosseini Asghar, Seyed Salehi Ali, Shahrokh Shabnam
Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Live Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gastroenterol Hepatol Bed Bench. 2019;12(Suppl1):S87-S93.
We conducted this study to estimate the direct medical cost of Iranian IBD patients.
In the economic evaluation setting, descriptive epidemiological studies can provide substantial information for health system policymakers in taking accountable decisions for diseases such as Inflammatory Bowel Disease (IBD).
To do so, we used a self-designed checklist to collect demographic and medical cost information for IBD patients. We also tried to have a national estimation of IBD costs.
The mean annual medical cost of IBD was 18354.52 PPP$. Crohn's disease (CD) vs. ulcerative colitis (UC) and UC township patients vs. Tehran resident patients had higher medical costs (31160.79 PPP$; P<0.001) and (20840.23 PPP$, P<0.025). The largest medical cost spent in both IBD subtypes (CD/UC) was attributed to biological agents, especially in UC patients. We estimated that the mean annual cost of IBD in Iran for 2017 was 746315864 (95% CI: 602964172, 964685749) PPP$ (constant incidence) and 862776811 (95% CI: 697055402, 1115222835) PPP$ (increment incidence) respectively.
Our results suggest that for management of IBD patients, policymakers should address shifting the medical costs to biological agents, the higher cost of CD, and the impact of underlying factors on the distribution of these medical costs.
我们开展本研究以估算伊朗炎症性肠病（IBD）患者的直接医疗费用。
在经济评估环境中，描述性流行病学研究可为卫生系统政策制定者在针对诸如炎症性肠病（IBD）等疾病做出可问责决策时提供大量信息。
为此，我们使用自行设计的清单收集IBD患者的人口统计学和医疗费用信息。我们还试图对IBD费用进行全国性估算。
IBD的年均医疗费用为18354.52国际元。克罗恩病（CD）与溃疡性结肠炎（UC）相比，以及UC乡镇患者与德黑兰居民患者相比，医疗费用更高（分别为31160.79国际元；P<0.001）和（20840.23国际元，P<0.025）。两种IBD亚型（CD/UC）中花费最多的医疗费用都归因于生物制剂，尤其是UC患者。我们估计，2017年伊朗IBD的年均费用分别为746315864（95%可信区间：602964172，964685749）国际元（恒定发病率）和862776811（95%可信区间：697055402，1115222835）国际元（递增发病率）。
我们的结果表明，对于IBD患者的管理，政策制定者应解决将医疗费用转向生物制剂、CD的较高成本以及潜在因素对这些医疗费用分布的影响等问题。
